LIVN · LivaNova PLC
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share non-GAAP | $1.26 | second quarter of 2026 | — |
|
|
|||
| Adjusted free cash flow non-GAAP | $45.5M | second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 66.6M
-31.6M Purchases of property, plant, and equipment
-0.2M Dividends received from investments
+10M Payment of contingent consideration included in cash provided by operating activities
+0.7M 3T Heater-Cooler litigation payments
= Adjusted free cash flow 45.5M
|
|||
| Adjusted operating income non-GAAP | $90.8M | second quarter of 2026 | — |
|
|
|||
| Net cash provided by operating activities | $254.3M | Full-Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIVN
this stock
LivaNova PLC
|
$4.49B | +32.4% | +10.7% | 24.0 | 7.5% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.9% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -5.6% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -5.7% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$74.64B | -46.1% | +12.5% | 20.9 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIVN | +6.5% | +2.9% | +18.0% | +1.7% | +32.4% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | +6.6% | -1.3% | +5.6% | -1.8% | +19.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.